Search results for "progressive"

showing 10 items of 281 documents

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis

2000

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis. Background Wegener's granulomatosis (WG) is characterized by systemic vasculitis with crescentic glomerulonephritis (CGN) and circulating autoantibodies directed against neutrophil cytoplasmic antigens (ANCA). Proteinase 3 (PR-3), a neutral serine proteinase in neutrophils implicated in the growth control of myeloid cells, has been identified as the target antigen for ANCA in WG. Since the kidneys are frequently involved in WG, we studied the in situ expression of PR-3 by renal parenchymal cells. Methods We assessed the expression of PR-3 in kidney biopsies of 15 patien…

AdultMalePathologymedicine.medical_specialtyBiopsyMyeloblastinKidney GlomerulusIn situ hybridizationBiologyurologic and male genital diseasesKidneyvasculitisAntigenProteinase 3medicineRapidly progressive glomerulonephritisHumanscrescent glomerulonephritisNorthern blotRNA Messengerrapidly progressive glomerulonephritisCells CulturedAgedKidneyANCAurogenital systemSerine EndopeptidasesGranulomatosis with PolyangiitisEpithelial CellsMiddle Agedmedicine.diseasekidney parenchymal cellsmedicine.anatomical_structureKidney TubulesNephrologyImmunohistochemistryFemaleSystemic vasculitisKidney International
researchProduct

Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: A case report

2002

Reversible posterior leukoencephalopathy syndrome (RPLS) is an uncommon entity related to multiple and different pathologies, the most common being hypertensive crisis. It is believed to be secondary to the breakdown on the blood-brain barrier. At the beginning, it is undistinguishable from other leukoencephalopathies. However, the disappearance of brain lesions after removal of the potential cause, establish the differential diagnosis with other leukoencephalopathies. We present the case of an HIV-infected patient with a RPLS related to a hypertensive crisis short after the initiation of indinavir-containing highly active antiretroviral therapy. Once blood pressure was controlled and indin…

AdultMalePathologymedicine.medical_specialtyHypertensive encephalopathymedicine.medical_treatmentHIV InfectionsIndinavirIndinavirAntiretroviral Therapy Highly ActiveHypertensive EncephalopathyInternal MedicinemedicineHumansChemotherapymedicine.diagnostic_testbusiness.industryProgressive multifocal leukoencephalopathyvirus diseasesMagnetic resonance imagingHIV Protease Inhibitorsmedicine.diseaseMagnetic Resonance ImagingHyperintensityNelfinavirDifferential diagnosisbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up.

2020

Background Hepatocellular adenomas (HCAs) are rare benign liver tumors. Guidelines recommend continued surveillance of patients diagnosed with HCAs, but these guidelines are mainly based on small studies or expert opinion. Purpose To analyze the long-term evolution of HCAs, including solitary and multiple lesions, and to identify predictive features of progression with MRI. Materials and Methods In a retrospective study, patients diagnosed with pathologically proven solitary or multiple HCAs between January 2004 and December 2015 were included; β-catenin-mutated HCAs and HCAs with foci of malignancy were considered to be at risk for progression. MRI examinations were analyzed, and tumor evo…

AdultMalePediatricsmedicine.medical_specialtyCarcinoma HepatocellularAdenomahepatocellular adenomaMEDLINEDiseaseliverMalignancyGastroenterology030218 nuclear medicine & medical imagingAdenoma Liver Cell03 medical and health sciencessymbols.namesakeText mining0302 clinical medicineMcNemar's testInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingFisher's exact testResponse Evaluation Criteria in Solid TumorsRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studymedicine.diseaseMagnetic Resonance ImagingTerm (time)Response Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesissymbolsDisease ProgressionFemalebusinessProgressive diseaseMRIFollow-Up StudiesRadiology
researchProduct

No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis

2011

AdultMalePrionsChromosomes Human Pair 20Primary Progressive Multiple SclerosisPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)HumansMedicineGenetic Predisposition to DiseasePrion proteinCodonGene030304 developmental biologyGenetics0303 health sciencesbusiness.industryMiddle AgedMultiple Sclerosis Chronic ProgressivePrnp geneFemaleNeurology (clinical)business030217 neurology & neurosurgeryArchives of Neurology
researchProduct

Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis

1996

There is mounting evidence that activated interleukin 2 (IL-2)-releasing lymphocytes play a central role in the immunopathogenesis of sarcoidosis by directing inflammatory reactions and granuloma formation. In the context that a significant proportion of these cells accumulates in the lung and releases mediators, we hypothesized that different immunologically defined stages of sarcoidosis can be identified. A cohort of 89 sarcoidosis patients was allocated to four groups according to the following criteria: stage A, a low number of bronchoalveolar lavage (BAL) lymphocytes (20%) without IL-2 release (1 unit/ml in BAL cell culture supernatant); stage B, BAL lymphocytes20%, with IL-2 release (…

AdultMalePulmonary and Respiratory MedicineInterleukin 2T-LymphocytesContext (language use)InflammationStatistics NonparametricPulmonary function testingSarcoidosis PulmonarymedicineHumansCells CulturedChi-Square DistributionLungmedicine.diagnostic_testbusiness.industryrespiratory systemPrognosismedicine.diseaserespiratory tract diseasesBronchoalveolar lavagemedicine.anatomical_structureImmunologyInterleukin-2FemaleSarcoidosismedicine.symptombusinessBronchoalveolar Lavage FluidProgressive diseaseFollow-Up Studiesmedicine.drugLung
researchProduct

Effect of sensory exposure on liking for fat- or sugar-reduced biscuits

2015

This study investigates the effect of exposure to fat- or sugar-reduced biscuits on liking for these products. Two sets of biscuits were manufactured, each including a standard variant and 4 variants differing by the level of reduction of either fat or sugar content, to 33% of fat content or 28% of sugar content. Biscuit consumers were recruited to eat either the fat (n ¼ 113) or the sugar-reduced set of biscuits (n ¼ 106). They participated in 5 testing sessions, once a week, in laboratory conditions. During each session, they rated their liking of the 5 variants. At the end of each of the 4 first sessions, consumers were given 16 biscuits for their home consumption during the week. Partic…

AdultMaleTasteliking030309 nutrition & dieteticsFat content[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionEnvironmentFood Supply03 medical and health sciencesFood PreferencesYoung Adult0404 agricultural biotechnologyFeeding behaviorDietary SucroseFood supplyReduced fatmedicineHumansFood scienceObesitySugarreduced sugarGeneral Psychology2. Zero hunger0303 health sciencesCommunicationNutrition and Dieteticsbusiness.industrybiscuit04 agricultural and veterinary sciencesBreadFeeding BehaviorMiddle Agedmedicine.disease040401 food scienceObesityDietary Fatsprogressive exposurereduced fatDietdirect exposureDirect exposureTasteFemalebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1

2008

We recently identified the X-chromosomal four and a half LIM domain gene FHL1 as the causative gene for reducing body myopathy, a disorder characterized by progressive weakness and intracytoplasmic aggregates in muscle that exert reducing activity on menadione nitro-blue-tetrazolium (NBT). The mutations detected in FHL1 affected highly conserved zinc coordinating residues within the second LIM domain and lead to the formation of aggregates when transfected into cells. Our aim was to define the clinical and morphological phenotype of this myopathy and to assess the mutational spectrum of FHL1 mutations in reducing body myopathy in a larger cohort of patients. Patients were ascertained via th…

AdultMaleWeaknessPathologymedicine.medical_specialtyMutation MissenseMuscle ProteinsBiologymedicine.disease_causeMuscular DiseasesBiopsymedicineHumansGenetic Predisposition to DiseaseMyopathyChildMicroscopy ImmunoelectronMuscle SkeletalMutationMuscle biopsymedicine.diagnostic_testIntracellular Signaling Peptides and ProteinsInfantGenetic Diseases X-LinkedOriginal ArticlesLIM Domain Proteinsmedicine.diseaseCongenital myopathyFHL1PedigreeChild PreschoolFemaleNeurology (clinical)medicine.symptomProgressive disease
researchProduct

Radiofrequency tissue volume reduction for treatment of auricle keloids

2010

Objectives/Hypothesis: Keloids are often refractive to treatment, and recurrences occur quite frequently. Radiofrequency tissue volume reduction (RFTVR) is a surgical technology that induces extensive fibrosis at the target tissues. Methods: We applied RFTVR in 14 patients (19 auricles, 5 patients treated bilaterally; 9 female, 5 male; range, 10–66 years) with keloids of the auricle. Keloids were located at the earlobe in 4 patients (5 auricles), helix in 9 patients (12 auricles), and at both earlobe and helix in 1 patient (2 auricles). In 6 patients (8 auricles) RFTVR was the sole treatment modality applied, and in 7 patients (10 auricles) intralesional steroid injection was also performed…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentYoung AdultFibrosisSurgical technologymedicineHumansMinimally Invasive Surgical ProceduresChildEar DiseasesReduction (orthopedic surgery)EarlobeAgedAuriclebiologybusiness.industryPinnaMiddle Agedbiology.organism_classificationmedicine.diseaseSurgerymedicine.anatomical_structureOtorhinolaryngologyKeloidCatheter AblationFemalebusinessProgressive diseaseEar AuricleTissue volumeThe Laryngoscope
researchProduct

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

2007

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of IVIG in primary (PPMS) and secondary (SPMS) chronic progressive MS. Two-hundred and thirty-one patients stratified for PPMS ( n = 34) and SPMS ( n = 197) were randomly assigned to IVIG 0.4 g/kg per month or to placebo for 24 months. Primary endpoints were 1) the time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and …

AdultMalemedicine.medical_specialtyDiseasePlaceboPlacebosCentral nervous system diseaseDisability EvaluationDegenerative diseaseQuality of lifeRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProspective StudiesDepression (differential diagnoses)AgedExpanded Disability Status Scalebusiness.industryMultiple sclerosisImmunoglobulins IntravenousMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseSurgeryTreatment OutcomeNeurologyDisease ProgressionFemaleNeurology (clinical)businessMultiple Sclerosis Journal
researchProduct